PRVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Privia Health Group Inc (PRVA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and hedge fund buying activity. Despite minor pre-market price decline and overbought technical indicators, the company's robust fundamentals and growth potential in the healthcare technology sector make it a solid long-term investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 83.326, suggesting the stock is overbought. Moving averages are converging, signaling potential consolidation. Key resistance levels are at 24.386 and 25.368, with support at 22.797 and 21.208.
Strong Q4 2025 financial performance with 17.4% revenue growth and 108.02% net income growth YoY. Hedge funds are significantly increasing their positions in the stock (+431.38% last quarter). Analyst coverage resumed with an Outperform rating and a $31 price target, citing growth potential in physician enablement and value-based care.
The stock is currently overbought based on RSI, which may lead to short-term price consolidation or pullback. Pre-market price is down by 0.12%, and technical analysis suggests a 70% chance of minor declines in the next day or week.
In Q4 2025, Privia Health reported a 17.42% YoY increase in revenue to $541.17 million, a 108.02% YoY increase in net income to $9.15 million, and a 133.33% YoY increase in EPS to $0.07. Adjusted EBITDA grew by 38.8% to $125.5 million. However, gross margin declined by 13.29% YoY to 8.68.
RBC Capital resumed coverage with an Outperform rating and a $31 price target. Analysts highlight Privia's growth potential in physician enablement, leveraging its payor-agnostic model and expanding physician network.
